UK Government Weighs Exit From £330M Palantir NHS Contract

The UK government is evaluating whether to terminate Palantir’s involvement in a £330 million NHS data platform contract, with a break clause triggering in spring 2027 providing the earliest exit route from a deal that has delivered only a fraction of promised capabilities while locking the health service into dependency on proprietary US software.

Speaking in a Westminster Hall debate on 16 April, Zubir Ahmed, junior minister for the Department of Health and Social Care, confirmed the government would assess alternative providers ahead of the break clause. “If, at the point of the break clause, we evaluate and find that there are other providers that can do the job better, then of course that needs to be looked at and reflected upon,” Ahmed told The Register.

The Federated Data Platform contract, awarded in 2023, was meant to integrate patient data across 240 NHS trusts by year-end. But deployment has fallen far short: approximately 200 trusts announced plans to join, only half went live, and just a quarter reported measurable benefits, according to parliamentary testimony presented during the debate. The initial three-year contract called for 13 core capabilities but has delivered only three or four, and those only partially.

The Vendor Lock-In Problem

The contract’s most contentious feature is its intellectual property terms. All specially written software — including the data collection infrastructure built to integrate NHS trusts — belongs to Palantir, per contract language reviewed during parliamentary testimony. This creates strategic dependency: switching providers would require rebuilding integration software from scratch, at unknown cost.

Chi Onwurah, chair of the Science, Innovation and Technology Select Committee, rejected Palantir’s framing of critics as ideologically opposed to data use. “There are issues around contract transparency, vendor lock-in, value for money and data security,” she told Computing. Labour MP Dawn Butler questioned whether the arrangement permits “AI and data sovereignty,” concluding “the answer to that will be no.”

The NHS lacks ownership of the custom integrations Palantir built to connect disparate trust systems — the very software that makes switching providers prohibitively complex. This mirrors concerns raised about Big Tech infrastructure contracts across Whitehall. Palantir has secured over £500 million in UK public sector work since 2020, including a £240 million Ministry of Defence analytics contract in December 2025, according to Medact.

Competing Return-on-Investment Claims

Palantir’s UK chief Louis Mosley argued in April that the platform was forecast to deliver £150 million in benefits by decade’s end — “a £5 return for every pound spent,” per Resultsense. But those projections rest on full deployment across 240 trusts, a target the programme is not on track to meet. Current adoption stands at 151 organisations, up from 118 last June but well short of year-end goals.

Campaign groups and unions dispute the value proposition. Over 47,000 patients wrote to local trust boards by February 2026 opposing Palantir’s involvement, citing the company’s work with US Immigration and Customs Enforcement and concerns about data sharing with law enforcement agencies under future governments. The British Medical Association advised doctors to limit engagement with the platform.

Leadership Exodus Signals Turbulence

The FDP’s performance shortfalls coincide with turnover among NHS England tech leadership who oversaw the Palantir procurement. CIO John Quinn left in March 2025. Chief data officer Ming Tang departed this month, and CTO Sonia Patel is leaving in April 2026, according to The Lowdown NHS. While organisations routinely experience leadership transitions, the concentration of exits among officials directly responsible for the programme’s strategic direction raises questions about internal confidence in its trajectory.

Health Secretary Wes Streeting has questioned whether NHS should partner with companies whose founders hold views opposed to public healthcare. Palantir co-founder Peter Thiel previously advocated for NHS privatisation and backed Brexit campaigns. Lord Patrick Vallance, the science minister, told Parliament in March he favoured “putting British companies there and procuring innovation here” rather than relying on US contractors for critical infrastructure.

What to Watch

The government’s feasibility assessment of alternative providers will determine whether the break clause triggers in spring 2027. Key tests include whether competitors can assume operation of the existing platform without rebuilding integration software, and at what cost. If IP ownership remains with Palantir, any switch would require NHS trusts to migrate to entirely new systems — a multi-year, high-risk undertaking that could make contract termination impractical regardless of political appetite.

Parliament’s scrutiny will focus on whether the government negotiated adequate IP transfer rights in the original 2023 contract, or whether procurement rules allowed a strategic lock-in scenario to develop unchecked. The decision will set precedent for how the UK handles vendor dependency in critical public infrastructure — particularly in AI and data systems where switching costs are asymmetrically high.

Palantir’s Mosley, speaking to The Register, welcomed continued scrutiny: “Every major government infrastructure program of this scale should be held under constant review.” Whether that review leads to contract renewal or termination will reveal whether the UK government believes it can afford to walk away from a platform that, despite fractured delivery, now holds integration software for half the NHS trusts in England.